Advanced non-small cell lung cancer – treatment with PembrolizumabQuestion: What is the impact of pembrolizumab, associated or not to chemotherapy, on the outcomes of overall mortality (death from any cause) and adverse events in the treatment of patients with advanced NSCLC when compared to chemotherapy alone?1
Answer: The treatment with Pembrolizumab, associated or not with chemotherapy, in adult patients with squamous or non-squamous NSCLC, locally advanced or metastatic, without previous systemic therapy, without mutations in the EGFR gene and gene rearrangement of the ALK, with a score of 0 or 1 in the ECOG performance scale, with at least one measurable lesion evaluated by Recist version 1.1, and PD-L1 expression [Tumor Proportion Score (TPS)] ≥1% (positive PDL-1). High quality of evidence.
